XL-880 effective

News of the day:

In pts [patients] with PRC, XL-880 demonstrated antitumor activity

Name	Target	Company	Phase
AZD-2171	Vegf c-Kit Pdgfr-β	AstraZeneca	ph2
AZD-2171	Vegf c-Kit Pdgfr-β	AstraZeneca	ph2
PD-325901	Mek	Pfizer	ph2
XL-647	ErbB1,2 Vegfr-2	Exelixis	ph2
XL-880	c-Met Vegf	Exelixis	ph2
ARQ-197	c-Met	Arqule	ph1
BAY-579352	Vegfr-2,3 c-Kit Pdgfr-β	Bayer	ph1
BAY-734506	c-Kit Ret Pdgfr Raf	Bayer	ph1
BIBW-2992	ErbB (irrev)	BI	ph1
PD-325901	Mek	Pfizer	ph1
PF-299804	ErbB (irrev)	Pfizer	ph1
Ticribine	Akt	VioQuest	ph1
XL-647	ErbB 1,2 Vegfr-2	Exelixis	ph1
XL-820	Vegfr c-Kit Pdgfr	Exelixis	ph1
XL-880	c-Met Vegf	Exelixis	ph1
ARRY-543	ErbB1, 2	Array	ph1
AT-13148	Akt Rock PKA	Astex
AV-951	Vegf	Aveo	ph1
BAY-734506	c-Kit Ret Pdgfr Raf	Bayer
BMS-698769	c-Met	BMS
CEP-11981	Tie2 Vegfr	Cephalon
CUDC-101	HDAC / ErbB	Curis
NVP-BEZ235	Pi3k	Novartis
OSI-906	IGF-1R	Osi
RDEA-119	Mek	Ardea
SGX-523	c-Met	SGX
SR-13654	Src	SRI
XL-765	Pi3k, mTOR	Exelixis
XL-820	c-Kit	Exelixis
XL-844	Chk1, 2	Exelixis
ZD-6474	Vegfr-2 EGFR
ZM 447439	Aurora
CRT-59359	PKD	CRT